Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Ping An Biomedical Announces 1-for-40 Reverse Stock Split

Ping An Insurance

Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on October 23, 2026

October 21, 2026 11:00 ET  | Source: Ping An Biomedical Co., Ltd

HONG KONG, Oct. 21, 2026 -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock split of the Company’s class A ordinary shares and class B ordinary shares.

The Company’s class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on October 23, 2026. The shares will continue to trade under the ticker symbol “PASW.”

At the extraordinary general meeting (the “EGM”) of shareholders of the Company held on 18 March 2026, at 9:00 a.m., Hong Kong Time, the following matters, among others, were approved and authorized that with effect on a date within one (1) calendar year after the conclusion of the EGM to be determined by the board of directors of the Company (the “Board”): (A) every one thousand (1,000) then issued and unissued class A ordinary shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class A ordinary share (the “Consolidated Class A Share(s)”), (B) every one thousand (1,000) then issued and unissued class B ordinary shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class B ordinary share (the “Consolidated Class B Share(s)”); (C) all fractional entitlements to the issued Consolidated Class A Shares and Consolidated Class B Shares resulting from the share consolidation will not be issued to the shareholders of the Company and instead, any fractional shares that would have resulted from the share consolidation will be rounded up to the next whole number; and (D) the Board be authorized and directed to do all such acts and things as it may consider necessary or desirable for the purpose of effectuating the share consolidation, including determining the definitive ratio and the effective date of the share consolidation and any other changes to the Company’s authorized share capital in connection with and as necessary to effect the share consolidation.

On August 6, 2026, the Board approved unanimously a share consolidation at the ratio of forty (40)-for-one (1) (the “Share Consolidation” or the “Reverse Stock Split”), to be effective on October 23, 2026 (the “Effective Date”), pursuant to which, on the Effective Date, each 40 issued and unissued class A ordinary shares will be automatically combined into one class A ordinary share, and each 40 issued and unissued class B ordinary shares will be automatically combined into one class B ordinary share. Following the Share Consolidation, the par value of each class A ordinary share and each class B ordinary share will be changed from $0.0000625 to $0.0025. All fractional shares resulting from the Share Consolidation will not be issued to shareholders; instead, any fractional entitlements will be rounded up to the next whole number.

As of the date hereof, the Company has 112,867,000 class A ordinary shares and 12,250,000 class B ordinary shares issued and outstanding. Following the share consolidation, the Company expects to have approximately 2,821,675 class A ordinary shares and 306,250 class B ordinary shares issued and outstanding, subject to adjustment for the rounding up of fractional shares. The new CUSIP number for the Company’s class A ordinary shares following the reverse stock split will be G5880S139.

In connection with the Share Consolidation, the Company amended and restated its memorandum and articles of association currently in effect to reflect the adjustment of the number of authorized ordinary shares, the number of class A ordinary shares and class B ordinary shares of the Company and the par value. As advised by our Cayman Islands counsel, Appleby, the Share Consolidation and the third amended and restated memorandum and articles of association may need to be approved and ratified by shareholders at a general meeting.

About Ping An Biomedical Co., Ltd

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.

Contact Data

For more information, please contact: Ping An Biomedical Co., Ltd. Email: Celestia Investor Relations Email:

  1. 中国平安打造国内首个脑健康全周期服务，“医险协同”防治阿尔茨海默病Companies: Ping An Insurance格隆汇10月21日｜10月21日，中国平安举办阿尔茨海默病主动管理与脑健康服务研讨会，发布全国首个脑健康服务管理方案，通过发挥“综合金融+医疗养老”战略优势，打造“筛、治、康、安、付”全周期、闭环式服务体系，推动实现阿尔茨海默病“早筛查、早诊断、早干预”，助力健康中国建设。 具体而言，在早筛阶段，该方案构建由轻到精的多维早筛矩阵，用户居家即可在线完成认知评估、基因检测与生物标志物等筛查，实现早发现、早评估。在诊疗与康复阶段，该方案覆盖全国数百家专病合作医院、副高及以上专家资源，提供名医直通与全程陪诊，打通前沿靶向药直购；并联合北大医疗康复医院，将数字化训练与远程专业指导结合，让患者康复更便捷。
  2. 小摩：内险第三季度疲弱业绩大致被市场消化 建议趁弱增持中国平安、中国人寿Companies: Ping An InsuranceChina Life Insurance Company（来源：财闻） 预计中国保险公司第三季度盈利非常疲弱，受中国股市波动影响，行业净利润或同比下跌53%，此前第二季度曾大幅增长223%。 摩根大通（JPM.US）发布研报称，预计中国保险公司第三季度盈利非常疲弱，受中国股市波动影响，行业净利润或同比下跌53%，此前第二季度曾大幅增长223%。不过，该行并不认为这会成为股价的主要下行压力，因首九个月净利润预计大致稳定、同比仅跌3%，盈警风险有限，2026年每股盈利预测在上半年强劲业绩后修订亦有限，而且该板块过去一个月已经跑输大市。 因此，该行建议利用疲软机会增持 中国平安 （02318.HK）及 中国人寿 （02628.HK），理由是其2027财年预期股息收益率分别达8%及4%，具吸引力，同时偿付能力资本稳健，合同服务边际稳步增长。年底前的关键催化剂包括第三季度业绩电话会议中公布的最终每股股息指引，以及政府可能推出的养老及长期护理政策支持，或附带税收优惠。 该行指出，第三季度疲弱业绩
  3. 中国平安(02318.HK)拟10月28日举行董事会会议审批第三季度业绩Companies: Ping An Insurance格隆汇9月24日丨中国平安(02318.HK)发布公告，谨定于2026年10月28日（星期三）举行董事会会议，以考虑及通过集团截至2026年9月30日止九个月的第三季度业绩，以及处理任何其他事项。
  4. FinancePing An Good Doctor Launches " Ping An GlobalCare": AI-Powered Multilingual Services Break Down Healthcare Barriers for Expats in ChinaCompanies: Ping An InsurancePing An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) recently unveiled its new product "Ping An GlobalCare" (平安跨境康) at the Shenzhen Sci-Tech Innovation Exhibition. Targeting the pain...
  5. HealthcareAM Best Affirms Credit Ratings of Ping An Health Insurance Company of China, Ltd.Companies: Ping An InsuranceHONG KONG, September 04, 2026--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a" (Excellent) of Ping An Health Insurance Company of China, Ltd. (Ping An Health) (China). The outlook of these Credit Ratings (ratings) is stable.
  6. FinancePing An Good Doctor Announces 2026 Interim ResultsCompanies: Ping An InsuranceCorporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement — Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its...